Pre-Clinical Development of Listeria-Based Nanovaccines as Immunotherapies for Solid Tumours: Insights From Melanoma

OncoImmunology - United States
doi 10.1080/2162402x.2018.1541534
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors

Technology in Cancer Research and Treatment
MedicineCancer ResearchOncology
2016English

Clinical and Molecular Insights Into BCG Immunotherapy for Melanoma

Journal of Internal Medicine
Internal Medicine
2020English

Estrogen Receptor Β in Melanoma: From Molecular Insights to Potential Clinical Utility

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2016English

Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms

Clinical and Developmental Immunology
2012English

Stem Cell-Based Therapies for Osteoarthritis: From Pre-Clinical to Clinical Applications

2017English

Organelle Targeting During Bacterial Infection: Insights From Listeria

Trends in Cell Biology
Cell Biology
2015English

A Clinical Lecture on Operations for Diseases of the Uterus and Solid Ovarian Tumours

BMJ
1904English

Molecular Imaging Biomarkers for Cell-Based Immunotherapies

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2017English

Checkpoint Blockade Inhibitors Enhances the Effectiveness of a Listeria Monocytogenes-Based Melanoma Vaccine

Oncotarget
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy